Jin Medical International Ltd

Análisis de la acción Jin Medical International Ltd (ZJYL)

$1.900

-0.089 (-4.69%)Al cierre

Loading chart…
Máximo
2.093
Apertura
1.970
Precio medio ponderado por volumen
1.95
Volumen
22.46K
Capitalización
402.33M
Mínimo
1.860
Importe
43.83K
EV/EBITDA, TTM
0.00

Jin Medical International Ltd is a holding company mainly engaged in the design and manufacturing of wheelchairs. The Company, through its wholly owned subsidiaries, is primarily engaged in the design, development, manufacturing and sales of wheelchair and other living aids products to be used by people with disabilities or impaired mobility. The Company's wheelchair product category includes mid, high and low-end wheelchairs. The wheelchair components include wheels and brakes, which are sold to customers for after-sales service. The living aids product category consists of oxygen concentrators, bath aids and rehabilitative devices. The Company mainly distributes its products in domestic and overseas markets.

Análisis de IA of Jin Medical International Ltd (ZJYL)

Mantener

Currently, Jin Medical International Ltd (ZJYL) is not a strong buy. The stock is trading at $2.05, which is significantly down 54.47% year-to-date and 67.17% over the past year. Although the RSI is at 48.154, indicating it is not overbought or oversold, the forward P/E ratio is exceptionally high at 147.30, suggesting that the stock may be overvalued. Additionally, the recent 1-for-20 reverse stock split has led to a 16% drop in premarket trading, raising concerns about investor confidence. The main risk is the stock's high valuation metrics, particularly the price-to-sales ratio of 7.76, which could deter long-term investors. Overall, while there are some positive projections based on historical patterns, the current financial indicators suggest caution.

Métricas de valoración

El PER previsto actual de Jin Medical International Ltd (ZJYL) es 0.00, frente a su media de 5 años de 0.00.

PER previsto

Muy infravalorado
Media 5A P/E
0.00
P/E actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

EV/EBITDA previsto

Muy infravalorado
Media 5A EV/EBITDA
0.00
EV/EBITDA actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

Precio/ventas previsto

Muy infravalorado
Media 5A P/S
0.00
P/S actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

Escenarios de precio de Alphio AI para ZJYL

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%ZJYL

$0.63

Precio del escenario

B

Base

Base · 50%ZJYL

$0.59

Precio del escenario

B

Bajista

Bajista · 25%ZJYL

$0.47

Precio del escenario

Cronología de eventos

2026-03-13 (ET)

20:00:00

Jin Medical International Ltd Trading Halted, News Pending

2025-07-16 (ET)

05:41:21

Jin Medical launches production at Plant No. 3

2025-05-06 (ET)

17:47:51

Jin Medical receives noncompliance notification from Nasdaq

2024-10-10 (ET)

08:11:23

Jin Medical announces initiation of construction of new manufacturing facility

Noticias

Preguntas frecuentes sobre ZJYL, respondidas por Alphio AI

Jin Medical International Ltd is a holding company mainly engaged in the design and manufacturing of wheelchairs. The Company, through its wholly owned subsidiaries, is primarily engaged in the design, development, manufacturing and sales of wheelchair and other living aids products to be used by people with disabilities or impaired mobility. The Company's wheelchair product category includes mid, high and low-end wheelchairs. The wheelchair components include wheels and brakes, which are sold to customers for after-sales service. The living aids product category consists of oxygen concentrators, bath aids and rehabilitative devices. The Company mainly distributes its products in domestic and overseas markets. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC, AND SURGICAL APPLIANCES AN industry).

Currently, Jin Medical International Ltd (ZJYL) is not a strong buy. The stock is trading at $2.05, which is significantly down 54.47% year-to-date and 67.17% over the past year. Although the RSI is at 48.154, indicating it is not overbought or oversold, the forward P/E ratio is exceptionally high at 147.30, suggesting that the stock may be overvalued. Additionally, the recent 1-for-20 reverse stock split has led to a 16% drop in premarket trading, raising concerns about investor confidence. The main risk is the stock's high valuation metrics, particularly the price-to-sales ratio of 7.76, which could deter long-term investors. Overall, while there are some positive projections based on historical patterns, the current financial indicators suggest caution.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar